[go: up one dir, main page]

ME03056B - Jedinjenja 3,4-diamino-6-hloropirazin-2-karboksamida za tretman bolesti posredovanih sa enac - Google Patents

Jedinjenja 3,4-diamino-6-hloropirazin-2-karboksamida za tretman bolesti posredovanih sa enac

Info

Publication number
ME03056B
ME03056B MEP-2018-185A MEP2018185A ME03056B ME 03056 B ME03056 B ME 03056B ME P2018185 A MEP2018185 A ME P2018185A ME 03056 B ME03056 B ME 03056B
Authority
ME
Montenegro
Prior art keywords
enac
chloropyrazine
diamino
treatment
mediated diseases
Prior art date
Application number
MEP-2018-185A
Other languages
German (de)
English (en)
French (fr)
Inventor
Susanne Elisabeth Berglund
Stephen Connolly
Martin Hemmerling
Nafizal Hossain
Anna Kristoffersson
Johan Rune Michael Lundkvist
Grigorios Nikitidis
Lena Elisabeth Ripa
Igor Shamovsky
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ME03056B publication Critical patent/ME03056B/me

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MEP-2018-185A 2014-03-18 2015-03-17 Jedinjenja 3,4-diamino-6-hloropirazin-2-karboksamida za tretman bolesti posredovanih sa enac ME03056B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461954674P 2014-03-18 2014-03-18
EP15713339.8A EP3119752B1 (en) 2014-03-18 2015-03-17 3,4-diamino-6-chloropyrazine-2-carboxamide compounds for the treatment of enac mediated diseases
PCT/GB2015/050765 WO2015140527A1 (en) 2014-03-18 2015-03-17 Chemical compounds

Publications (1)

Publication Number Publication Date
ME03056B true ME03056B (me) 2018-10-20

Family

ID=52780553

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2018-185A ME03056B (me) 2014-03-18 2015-03-17 Jedinjenja 3,4-diamino-6-hloropirazin-2-karboksamida za tretman bolesti posredovanih sa enac

Country Status (39)

Country Link
US (3) US9873678B2 (me)
EP (1) EP3119752B1 (me)
JP (1) JP6502469B2 (me)
KR (1) KR102296041B1 (me)
CN (1) CN106103423B (me)
AP (1) AP2016009447A0 (me)
AR (1) AR099790A1 (me)
AU (1) AU2015233195B2 (me)
CA (1) CA2941807C (me)
CL (1) CL2016002303A1 (me)
CR (1) CR20160479A (me)
CY (1) CY1120509T1 (me)
DK (1) DK3119752T3 (me)
DO (1) DOP2016000232A (me)
EA (1) EA029952B1 (me)
ES (1) ES2679618T3 (me)
GT (1) GT201600190A (me)
HR (1) HRP20181123T1 (me)
HU (1) HUE039425T2 (me)
IL (1) IL247610B (me)
LT (1) LT3119752T (me)
ME (1) ME03056B (me)
MX (1) MX368577B (me)
NI (1) NI201600134A (me)
NZ (1) NZ724063A (me)
PE (1) PE20170205A1 (me)
PH (1) PH12016501808A1 (me)
PL (1) PL3119752T3 (me)
PT (1) PT3119752T (me)
RS (1) RS57487B1 (me)
SG (1) SG11201607751SA (me)
SI (1) SI3119752T1 (me)
SM (1) SMT201800378T1 (me)
SV (1) SV2016005278A (me)
TR (1) TR201810207T4 (me)
TW (1) TWI687410B (me)
UY (1) UY36034A (me)
WO (1) WO2015140527A1 (me)
ZA (1) ZA201607136B (me)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7608847B2 (ja) * 2021-01-27 2025-01-07 三菱瓦斯化学株式会社 エポキシ樹脂硬化剤、エポキシ樹脂組成物、及び塗料
GB202406247D0 (en) 2024-05-03 2024-06-19 Enterprise Therapeutics Ltd Compounds and pharmaceutical compositions

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577418A (en) 1969-02-12 1971-05-04 Merck & Co Inc Pyrazinamide derivatives and processes for their preparation
US3573306A (en) 1969-03-05 1971-03-30 Merck & Co Inc Process for preparation of n-substituted 3,5-diamino-6-halopyrazinamides
FI820266L (fi) 1981-02-02 1982-08-03 Ici Plc Alkanolaminderivater
EP0086564B1 (en) 1982-01-29 1985-11-21 Imperial Chemical Industries Plc Alkanolamine derivatives
GB8810934D0 (en) 1987-05-26 1988-06-15 Ici America Inc Amides
GB8810933D0 (en) 1987-05-26 1988-06-15 Ici America Inc Heterocyclic compounds
US4803206A (en) 1988-03-07 1989-02-07 Schering Corporation Antihypertensive acylpyrazines
GB8812342D0 (en) 1988-05-25 1988-06-29 Ici America Inc Bicyclic compounds
GB8812343D0 (en) 1988-05-25 1988-06-29 Ici America Inc Amino compounds
ID23789A (id) 1997-02-26 2000-05-11 Pfizer Turunan-turunan amida heteroaril-heksanoat, pembuatannya dan penggunaannya sebagai penghambat selektif dari mip-1, alfa yang diikat ke reseptor ccr1-nya
GB9930557D0 (en) 1999-12-23 2000-02-16 Rolic Ag Optically active materials
CA2876779A1 (en) 2000-05-12 2001-11-22 Genzyme Corporation Modulators of tnf-.alpha. signaling
RS50504A (sr) 2001-11-08 2007-04-10 Elan Pharmaceuticals Inc., Derivati n,n'-supstituisanog-1,3- diamino-2-hidroksipropana
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040087571A1 (en) 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
BR0317426A (pt) 2002-12-20 2005-11-16 Pfizer Prod Inc Inibidores de proteìna de transferência de triglicéridos microssomais
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
WO2006044381A2 (en) 2004-10-13 2006-04-27 University Of Connecticut Cannabinergic lipid ligands
GB0511065D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
AU2008221263B2 (en) 2007-03-01 2012-02-23 Novartis Ag Pim kinase inhibitors and methods of their use
BRPI0811562A2 (pt) 2007-05-07 2014-12-09 Novartis Ag Compostos orgânicos
PT2444120T (pt) 2007-12-10 2018-01-03 Novartis Ag Análogos da amilorida espirocíclicos como bloqueadores de enac
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8664228B2 (en) 2008-05-13 2014-03-04 Novartis Ag 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
WO2009150137A2 (en) * 2008-06-10 2009-12-17 Novartis Ag Organic compounds
WO2011028740A1 (en) 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
US9505735B2 (en) 2012-06-21 2016-11-29 Whitehead Institute For Biomedical Research Compounds for treating infectious diseases
CA2896686A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
RU2015129065A (ru) 2012-12-17 2017-01-25 Пэрион Сайенсиз, Инк. Производные хлор-пиразинкарбоксамида, обладающие активностью блокирования эпителиальных натриевых каналов

Also Published As

Publication number Publication date
PL3119752T3 (pl) 2018-09-28
AP2016009447A0 (en) 2016-09-30
US9873678B2 (en) 2018-01-23
TWI687410B (zh) 2020-03-11
NI201600134A (es) 2017-03-13
AR099790A1 (es) 2016-08-17
RS57487B1 (sr) 2018-10-31
US10336725B2 (en) 2019-07-02
LT3119752T (lt) 2018-08-10
IL247610A0 (en) 2016-11-30
ES2679618T3 (es) 2018-08-29
TW201620880A (zh) 2016-06-16
WO2015140527A1 (en) 2015-09-24
CN106103423A (zh) 2016-11-09
NZ724063A (en) 2018-02-23
EA201691641A1 (ru) 2017-02-28
CY1120509T1 (el) 2019-07-10
DOP2016000232A (es) 2016-10-16
MX368577B (es) 2019-10-08
US20190330187A1 (en) 2019-10-31
AU2015233195B2 (en) 2017-04-20
HRP20181123T1 (hr) 2018-09-21
PH12016501808B1 (en) 2017-01-09
SV2016005278A (es) 2016-11-30
ZA201607136B (en) 2018-04-25
CN106103423B (zh) 2019-12-06
EP3119752B1 (en) 2018-05-16
CA2941807A1 (en) 2015-09-24
SMT201800378T1 (it) 2018-09-13
TR201810207T4 (tr) 2018-08-27
EP3119752A1 (en) 2017-01-25
PT3119752T (pt) 2018-07-24
KR102296041B1 (ko) 2021-08-30
JP6502469B2 (ja) 2019-04-17
US20180162838A1 (en) 2018-06-14
GT201600190A (es) 2019-07-29
US10954211B2 (en) 2021-03-23
AU2015233195A1 (en) 2016-09-22
SG11201607751SA (en) 2016-10-28
US20170107195A1 (en) 2017-04-20
KR20160127135A (ko) 2016-11-02
CL2016002303A1 (es) 2017-01-13
MX2016011681A (es) 2016-10-28
EA029952B1 (ru) 2018-06-29
IL247610B (en) 2019-05-30
UY36034A (es) 2015-09-30
HUE039425T2 (hu) 2018-12-28
PH12016501808A1 (en) 2017-01-09
CR20160479A (es) 2017-02-24
SI3119752T1 (en) 2018-08-31
DK3119752T3 (en) 2018-07-30
PE20170205A1 (es) 2017-04-06
JP2017512830A (ja) 2017-05-25
CA2941807C (en) 2023-03-07

Similar Documents

Publication Publication Date Title
EP3263132C0 (en) COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IL-6
IL264049A (en) Compounds, preparations and methods for treating the disease
EP3634417C0 (en) QUINAZOLINE-PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS
EP3684418C0 (en) COMPOUNDS FOR THE TREATMENT OF CYSTEAMINE-RESPONSIVE DISORDERS
IL253062A0 (en) Pyrazine compounds for the treatment of infectious diseases
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
IL264156A (en) Compounds, preparations and methods for treating the disease
IL247452A0 (en) Compounds for treatment of complement mediated disorders
EP3193862C0 (en) TOPICAL COMPOSITION OF CANNABINOIDS FOR THE TREATMENT OF ARTHRITIS PAIN
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
EP4056208C0 (en) BLOOD PROCESSING SYSTEMS
EP4088724C0 (en) ACETYLCHOLINESTERASE INHIBITORS FOR THE ORAL TREATMENT OF DERMATOLOGICAL CONDITIONS
EP3405188A4 (en) Treatment for modulating gut microbiota
EP3359521C0 (en) NEW COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASE
EP3673900C0 (en) NASAL POWDER FORMULATION FOR THE TREATMENT OF HYPOGLYCEMIA
EP3177311C0 (en) COMBINATION OF MEDICINAL PRODUCTS CONTAINING CABOZANTINIB AND A PROTEASOME INHIBITOR FOR THE TREATMENT OF MULTIPLE MYELOMA
LT3210973T (lt) Heteroarilo junginiai, skirti akių ligų gydymui
EP3569238A4 (en) COMPOSITION FOR TREATING NEWBORN EHI
EP3283115C0 (en) COMPOSITIONS FOR THE TREATMENT OF AUTISM
EP3638252A4 (en) Sting-dependent activators for treatment of disease
EP3352684C0 (fr) Système pour le traitement d'une épistaxis
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
EP3577224A4 (en) NEW TREATMENT FOR NEAT1-ASSOCIATED ILLNESS
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
HUE063820T2 (hu) Módszerek kardiovaszkuláris betegségek kezelésére